Starpharma share price bolts 14% on COVID-19 nasal spray

The Starpharma share price has bolted more than 14% after the company provided an update on its nasal spray for COVID-19.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Starpharma Holdings Limited (ASX: SPL) share price bolted more than 14% in early trade today. The positive price action follows an announcement from the company regarding a nasal spray for COVID-19.

Details on Starpharma's nasal spray

Earlier today, Starpharma provided the market with an update on its SPL7013 nasal spray, which is currently being repurposed for treatment of COVID-19.

In the update, Starpharma announced progress with the development, regulation and manufacturing activities of its repurposed SPL7103 nasal spray. The company informed investors that it has identified a manufacturer and undertaken a pilot manufacture.

Starpharma also highlighted promising results from the antiviral testing for SPL7013. The company noted that testing had shown that SPL7013 has potent antiviral effect against COVID-19. The company provided supporting data which elaborated on the mechanism of action of SPL7013 in acting early in the viral replication cycle of COVID-19.

The data also indicated that potent activity of SPL7013 against COVID-19 was evident before and after exposure to the virus. Starpharma highlighted that the company has compiled regulatory documentation in preparation for submission. The company also noted that a regulatory pathway has been confirmed for a number of important markets including Europe.

Starpharma's management elaborated the important role that SPL7013 can play in fighting the COVID-19 pandemic. The company conceded that although a vaccine against the virus is most important, auxiliary products will help reduce the risk of transmission and exposure. Starpharma also noted that a publication of the antiviral data has been submitted to peer reviewed scientific journal.

More details on Starpharma

Starpharma is an Australian based biopharmaceutical company that develops products for pharmaceutical, life science and other applications. The company's underlying technology is built around a type of synthetic nanoscale polymer called dendrimers. Starpharma has 2 core development programs based on dendrimers: VivaGel and DEP drug delivery.

Earlier this year Starpharma announced that the active component of its VivaGel product, SPL7013 had shown significant activity against COVID-19. Since VivaGel is already approved in Europe, Canada, Australia and other countries, Starpharam believes that the company can fast-track development for products that target COVID-19.

Foolish takeaway

At the time of writing the Starpharma share price is trading more than 10% higher for the day at around $1.16. Shares in the company have been sold-down slightly after hitting an intra-day high of $1.22 earlier.

Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »